Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
Annals of General Psychiatry|July 13, 2013
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesMichael Markowitz, Dong-Jing Fu, Bennett Levitan, et al.
Psychopharmacology Bulletin|November 17, 2007
Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trialGahan J Pandina, Carla M Canuso, Ibrahim Turkoz, et al.
BMC Psychiatry|February 25, 2014
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitateJennifer Kern Sliwa, Dong-Jing Fu, Cynthia A Bossie, et al.
Neuropsychiatric Disease and Treatment|September 8, 2012
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al.
Journal of Affective Disorders|March 23, 2013
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depressionIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
International Clinical Psychopharmacology|July 20, 2016
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophreniaBennett Levitan, Michael Markowitz, Ibrahim Turkoz, et al.
The Journal of Clinical Psychiatry|February 12, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorderJaspreet S Brar, Rohan Ganguli, Gahan Pandina, et al.
The Journal of Clinical Psychiatry|June 23, 2017
Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of PaliperidonePeter J Weiden, Edward Kim, Jason Bermak, et al.
CNS Spectrums|July 29, 2022
Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIREIbrahim Turkoz, Oliver Lopena, Giacomo Salvadore, et al.
Neuropsychiatric Disease and Treatment|May 8, 2018
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL studyHuafang Li, Yan Li, Yu Feng, et al.
Pageof 10